Table 4.
Clinical-demographic description of the cross-sectional sample.
| Parameter | Transversal study | Longitudinal study |
|---|---|---|
| Sample size |
n = 25 participants n = 30 drugs |
n = 31 participants n = 36 drugs |
| Sex | ||
| Men Women |
n = 14 men n = 11 women |
n = 20 men n = 16 women |
| Current age (years) | 48.8 (13.5) | 50.9 (13.7) |
| Age at diagnosis (years) | 41.7 (12.9) | 43.2 (13.7) |
| Time since onset (years) | 6.4 (4.5) | 6.4 (4.9) |
| Surgery | ||
| Yes No |
n = 22 n = 3 |
n = 26 n = 5 |
| Number of surgeries | ||
| 1 2 |
n = 19 n = 3 |
n = 21 n = 5 |
| Surgery at external site | ||
| Yes No |
n = 6 n = 16 |
n = 6 n = 20 |
| Radiotherapy | ||
| Yes No |
n = 14 n = 11 |
n = 14 n = 17 |
| Therapeutic modality | ||
| Surgery only Surgery and radiotherapy None |
n = 8 n = 14 n = 3 |
n = 12 n = 14 n = 5 |
| Immunostaining* | ||
| GH GH + PRL GH + TSH |
n = 11 n = 9 n = 0 |
n = 12 n = 11 n = 1 |
| Granule density** | ||
| Low Dense |
n = 12 n = 2 |
n = 14 n = 3 |
| Type 2 diabetes mellitus diagnosis*** | ||
| Yes No |
n = 12 n = 8 |
n = 13 n = 18 |
| Type 2 diabetes mellitus treatment | ||
| DPP4i GLP1Ra basal insulin ultrarapid insulin metformin SGLT2i sulfonylurea |
n = 1 n = 0 n = 2 n = 2 n = 12 n = 2 n = 1 |
n = 2 n = 2 n = 1 n = 0 n = 15 n = 2 n = 2 |
*n = 2 participants at external site did not provide immunostaining results.
**n = 8 participants did not have granule density in their pathology report.
***In the case of the longitudinal study, this refers to diagnosis of T2DM at the end of the follow-up period.